4,901 trials
Neoplasms
Primary: Number of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs) — 3; 3; 14; 3 Participants
Carcinoma, Renal Cell
Primary: Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT) — 0 participants
Asthma
Primary: Percent Change From Baseline in Percent (%) Eosinophils in Induced Sputum At 8 Hours Post Allergen — -10.6; -7.3; 11.6 Percent change — p=0.011
Depressive Disorder
Primary: Part 1: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) — 41.7; 66.7; 66.7; 50.0 percentage of participants
Renal Impairment
Primary: Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine — 64.5; 45.1 μM•hr
Renal Insufficiency, Chronic · Kidney Disease, Chronic
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Smoking Cessation
Primary: Plasma Cytisine Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) — 22.9; 30.8 ng/mL
Ebola Virus Disease
Primary: Safety and Tolerability of Administration of ChAd3-EBO Z and MVA-EBO Z 7 Days Later. This Will be Done by Recording the Number of Participants Who Experience Adverse…
Influenza
Primary: Percentage of Participants With Immediate Reactions — 0; 0; 28; 10 Participants
Schizophrenia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 10; 10; 17; 14 Participants
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Assessment of Plasma CAB Pharmacokinetic (PK) Parameter: Area Under the Concentration-time Curve Over One Dosing Interval (AUC [0 to Tau]) — 103.978; 81.715 Microgram *…
Iron-refractory, Iron-deficiency Anemia (IRIDA)
Primary: Pharmacokinetics (PK) of Total Iron From Triferic Administered Orally in Adult Healthy Patients: Cmax — 140; 62.0; 32.4; 51.9 microgram/deciliter
Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLT) — 0; 0; 3; 2 participants
End Stage Renal Disease
Primary: Pharmacokinetics (PK) of Triferic Iron Administered Via Hemodialysate in Adult CKD-5HD Patients: Cmax. — 124; 131; 124 microgram per deciliter
End Stage Renal Disease
Primary: Pharmacokinetics of Triferic Iron Administered IV to Healthy Adults: Maximum Drug Concentration (Cmax) of Total Serum Iron — 102; 44.1 microgram/deciliter